Live Price Coverage: Could Concert Pharmaceuticals Inc Lose Strenght? The Stock Increases A Lot Today

Live Price Coverage: Could Concert Pharmaceuticals Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) is a huge mover today! About 166,866 shares traded hands or 68.13% up from the average. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has declined 31.08% since April 8, 2016 and is downtrending. It has underperformed by 36.73% the S&P500.
The move comes after 7 months positive chart setup for the $258.47M company. It was reported on Nov, 10 by Barchart.com. We have $13.53 PT which if reached, will make NASDAQ:CNCE worth $93.05M more.

Concert Pharmaceuticals Inc (NASDAQ:CNCE) Ratings Coverage

Out of 7 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Concert Pharmaceuticals has been the topic of 9 analyst reports since August 12, 2015 according to StockzIntelligence Inc. On Wednesday, August 12 the stock rating was initiated by Brean Capital with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 1. On Tuesday, September 22 the stock rating was maintained by Roth Capital with “Buy”. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The rating was initiated by Aegis Capital with “Buy” on Wednesday, September 9. The stock has “Neutral” rating given by UBS on Monday, November 9. As per Tuesday, September 22, the company rating was maintained by TH Capital.

According to Zacks Investment Research, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States.”

Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.36, from 1.03 in 2016Q1. The ratio improved, as 8 funds sold all Concert Pharmaceuticals Inc shares owned while 25 reduced positions. 11 funds bought stakes while 35 increased positions. They now own 13.09 million shares or 2.13% less from 13.37 million shares in 2016Q1.
Wells Fargo Co Mn holds 0% or 31,999 shares in its portfolio. Nationwide Fund Advisors last reported 0% of its portfolio in the stock. Blackrock Investment Limited Liability Co owns 64,532 shares or 0% of their US portfolio. Millennium Management Limited Liability Corp accumulated 0.01% or 284,421 shares. New York State Common Retirement Fund, a New York-based fund reported 16,200 shares. King Wealth Management Gru Ltd accumulated 30,882 shares or 0.19% of the stock. Cubist Systematic Strategies Limited Liability accumulated 1,134 shares or 0% of the stock. The United Kingdom-based Barclays Pcl has invested 0% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). The New York-based Teachers Inc has invested 0% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). Proshare Advsrs Ltd Com, a Maryland-based fund reported 18,558 shares. Ladenburg Thalmann accumulated 0% or 142 shares. Swiss Bank & Trust, a Switzerland-based fund reported 27,792 shares. Acadian Asset Management Limited Liability Com holds 0.02% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 275,138 shares. Rhumbline Advisers accumulated 17,248 shares or 0% of the stock. Awm Invest has 100,000 shares for 0.24% of their US portfolio.

More notable recent Concert Pharmaceuticals Inc (NASDAQ:CNCE) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on February 14, 2014, also Businesswire.com with their article: “Concert Pharmaceuticals Expands Management Team” published on September 06, 2016, Businesswire.com published: “Concert Pharmaceuticals Achieves $2 Million Milestone from Avanir …” on November 16, 2015. More interesting news about Concert Pharmaceuticals Inc (NASDAQ:CNCE) were released by: Seekingalpha.com and their article: “Concert Pharmaceuticals: At 52 Week Lows With Upcoming Catalysts” published on October 18, 2016 as well as Businesswire.com‘s news article titled: “Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” with publication date: August 09, 2016.

CNCE Company Profile

Concert Pharmaceuticals, Inc., incorporated on April 12, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of small molecule drugs. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. The Firm has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Firm is utilizing its DCE Platform to discover and develop product candidates for a range of indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment